Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Current Deferred Revenue: 2022-2025

  • Immunocore Holdings' Current Deferred Revenue was N/A to $582,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $582,000, marking a year-over-year change of. This contributed to the annual value of $7.8 million for FY2022, which is N/A change from last year.
  • As of Q3 2025, Immunocore Holdings' Current Deferred Revenue stood at $582,000, which was down 2.02% from $594,000 recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' Current Deferred Revenue ranged from a high of $7.8 million in Q4 2022 and a low of $582,000 during Q3 2025.
  • For the 1-year period, Immunocore Holdings' Current Deferred Revenue averaged around $588,000, with its median value being $588,000 (2025).